How were Innovate Biopharmaceuticals' earnings last quarter?

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) posted its quarterly earnings results on Monday, March, 18th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11).

What other stocks do shareholders of Innovate Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO) , Corbus Pharmaceuticals (CRBP) , AcelRx Pharmaceuticals (ACRX) , Iterum Therapeutics (ITRM) , SCYNEXIS (SCYX) , Micron Technology (MU) , Nabriva Therapeutics (NBRV) , Neurotrope (NTRP) and

NASDAQ:INNT

Innovate Biopharmaceuticals (INNT) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free INNT Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.56
▼
$1.42
52-Week Range: N/A

Volume: N/A
Average Volume: 525,982 shs
Market Capitalization: $8,000.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Headlines Social Media

Get Innovate Biopharmaceuticals alerts:

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Innovate Biopharmaceuticals Stock (NASDAQ:INNT)

Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

INNT Stock News Headlines

April 18, 2024 | finanznachrichten.de

Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy

April 15, 2024 | finance.yahoo.com

Third Harmonic Bio Inc CEO Natalie Holles Sells 13,558 Shares

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 15, 2024 | finance.yahoo.com

American Thoracic Society Selects Vasomune Therapeutics, Inc., to Present the AV-001 Development Update at the 2024 Respiratory Innovation Summit

April 12, 2024 | tmcnet.com

University of Phoenix Office of Educational Equity Leadership Presents at 2024 OLC Innovate Conference

April 10, 2024 | finanznachrichten.de

Monopar Therapeutics Inc.: Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

April 10, 2024 | finanznachrichten.de

IN8bio, Inc: IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

April 9, 2024 | finance.yahoo.com

NIIMBL Announces $10M for 8 New Biopharmaceutical Manufacturing Projects

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 9, 2024 | stockhouse.com

Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

April 9, 2024 | tmcnet.com

Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024

April 4, 2024 | finance.yahoo.com

Cadenza Bio, Inc. Appoints Michael A. Panzara, MD, MPH, to its Board of Directors

March 29, 2024 | finanznachrichten.de

SAB Biotherapeutics, Inc.: SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

March 28, 2024 | finanznachrichten.de

Monopar Therapeutics Inc.: Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

March 28, 2024 | finanznachrichten.de

XtalPi Inc.: XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

March 26, 2024 | finanznachrichten.de

Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

March 25, 2024 | finance.yahoo.com

Aptamer Sciences Inc. Files IND Application for Innovative Liver Cancer Treatment AST-201: A Promising Approach to Address Under Medical Needs

March 20, 2024 | markets.businessinsider.com

Janux Therapeutics: A Strong Buy on Innovative Cancer Therapies and Solid Financials

March 20, 2024 | finanznachrichten.de

TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Update on Clinical Programs

March 20, 2024 | msn.com

The problems and promise within Syracuse’s innovation economy

March 20, 2024 | markets.businessinsider.com

Buy Rating Endorsed for Azitra Inc. on Strong Pipeline and Financial Stability

March 18, 2024 | finance.yahoo.com

Alpine Immune Sciences Inc (ALPN) Reports Full Year 2023 Financial Results

March 18, 2024 | finanznachrichten.de

Clearside Biomedical, Inc.: Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

March 15, 2024 | finanznachrichten.de

IN8bio, Inc: IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

March 15, 2024 | finanznachrichten.de

JanOne Inc.: JanOne Regains Compliance with Nasdaq's Listing Requirements

March 15, 2024 | finanznachrichten.de

Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

March 15, 2024 | finance.yahoo.com

Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials

See More Headlines

Receive INNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innovate Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2019
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:INNT
CUSIP: N/A
CIK: 1551986
Web: www.innovatebiopharma.com
Phone: 919-275-1933
Fax: N/A
Employees: 8
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,050,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -234.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.35
Quick Ratio: 0.35

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.27) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 41,325,000
Free Float: N/A
Market Cap: $8,000.00
Optionable: Not Optionable
Beta: -0.39

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Sandeep Laumas M.D. (Age 50)
CEO & Exec. Chairman
Mr. Jay P. Madan M.S. (Age 53)
Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director
Dr. Christopher P. Prior (Age 66)
Consultant
Jerry Gardner M.D.
Head of Clinical Strategy
Dr. Patrick H. Griffin (Age 64)
Chief Medical Officer

Key Competitors

View All Competitors

INNT Stock Analysis - Frequently Asked Questions

How were Innovate Biopharmaceuticals' earnings last quarter?: Innovate Biopharmaceuticals Inc (NASDAQ:INNT) posted its quarterly earnings results on Monday, March, 18th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11).
What other stocks do shareholders of Innovate Biopharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), Iterum Therapeutics (ITRM), SCYNEXIS (SCYX), Micron Technology (MU), Nabriva Therapeutics (NBRV), Neurotrope (NTRP) and

This page (NASDAQ:INNT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Innovate Biopharmaceuticals (INNT) Stock Price, News & Analysis

About Innovate Biopharmaceuticals Stock (NASDAQ:INNT)

INNT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

INNT Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info